Repurposing of cefpodoxime proxetil as potent neuroprotective agent through computational prediction and in vitro validation
- 8 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (11), 3975-3985
- https://doi.org/10.1080/07391102.2020.1772884
Abstract
In recent reports, NR2B-NMDA receptor antagonists showed more research value because of its strong targeting ability and less side effects potential. In 2016, EVT-101 was reported to bind in an almost entirely new binding region of this target. Whether strikingly different binding modes can improve targeting and reduce side effects is worth studying. In our preliminary work, we explored the binding patterns of ifenprodil and EVT-101, found the key amino acids and summarized the pharmacophores, hoping to find such antagonists that target the two binding modes simultaneously. In this study, we developed a scalable virtual screening workflow in the FDA-approved drugs library to identify novel NR2B-NMDAR antagonists based on the combination of two pharmacophores. Cefpodoxime proxetil (5) was identified as the hit compound, and it was found for the first time that 5 might have neuroprotective activity as a NR2B-NMDAR antagonist. This result interested us to make further study, the ligand-receptor interactions modeled by molecular docking studies showed that the compound could perfectly merge both the pharmacophore characteristics of ifenprodil and EVT-101 at the binding cavity between the ATDs of GluN1 and GluN2B. The accuracy of molecular docking results and binding stability of ligand-receptor complexes were validated through 100 ns molecular dynamics simulation and binding free energy calculation. Afterwards, MTT assay (49.8%±0.1%, 5 μM) on NMDA injured SH-SY5Y cells and evidence of the effect on attenuating Ca2+ influx induced by NMDA were applied to validate the computational results, further investigation showed that 5 could suppress the NR2B upregulation induced by NMDA.Keywords
Funding Information
- National Natural Science Foundation of China (21977074)
- Science and Technology Projects from the Educational Department of Liaoning Province, China (2019LQN02)
- Overseas Expertise Introduction Project for Discipline Innovation (D20029)
- Program for Innovative Talents of Higher Education of Liaoning (2012520005)
This publication has 39 references indexed in Scilit:
- Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulationsComputational Biology and Chemistry, 2018
- NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an updateNeuropharmacology, 2018
- AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's DiseaseThe Consultant Pharmacist, 2017
- Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding SimulationsACS Omega, 2017
- Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B‐Selective NMDA Receptor Antagonists with a Benzo[7]annulen‐7‐amine ScaffoldChemMedChem, 2017
- The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: an animal model for cognitive symptoms of schizophreniaJournal of Physiology-Paris, 2013
- GluN2B subunit-containing NMDA receptor antagonists prevent Aβ-mediated synaptic plasticity disruption in vivoProceedings of the National Academy of Sciences of the United States of America, 2009
- Computational Studies to Discover a New NR2B/NMDA Receptor Antagonist and Evaluation of Pharmacological ProfileChemMedChem, 2008
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking AccuracyJournal of Medicinal Chemistry, 2004
- (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate ResponsesJournal of Medicinal Chemistry, 1995